SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China )
Also on site :
- Final Palisades fire evacuation order lifted
- Chart-Topping 70's Rock Band Honors Fallen Members During Farewell Show
- 'Unprecedented' number of US Air Force aerial refueling tankers heading toward Europe